Provided by Tiger Fintech (Singapore) Pte. Ltd.

MAIA Biotechnology Inc.

2.10
+0.05002.44%
Volume:238.48K
Turnover:477.01K
Market Cap:62.13M
PE:-2.00
High:2.10
Open:2.05
Low:1.90
Close:2.05
Loading ...

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

Business Wire
·
25 Feb

Amex Halt News Pending Lst 1.845100

THOMSON REUTERS
·
19 Feb

MAIA Biotechnology to sell 1.81M shares at $1.50 in private placement

TIPRANKS
·
19 Feb

Maia Biotechnology : to Use Proceeds Received From Private Placement to Fund Starting Cost for Part C of Phase Ii Trial Thio -101

THOMSON REUTERS
·
19 Feb

Maia Biotechnology Announces Private Placement of $2,715,000

THOMSON REUTERS
·
19 Feb

MAIA Biotechnology Announces Private Placement of $2,715,000

Business Wire
·
19 Feb

Maia Biotechnology Inc trading halted, news pending

TIPRANKS
·
19 Feb

MAIA Biotechnology Updates Executive Compensation Packages

TIPRANKS
·
07 Feb

Noble Financial Keeps Their Buy Rating on MAIA Biotechnology, Inc. (MAIA)

TIPRANKS
·
05 Feb

MAIA Biotechnology Reports Promising Phase 2 Trial Results

TIPRANKS
·
05 Feb

BUZZ-MAIA Biotechnology rises on lung cancer drug trial data

Reuters
·
05 Feb

MAIA Biotechnology announces updated data from THIO-101 trial

TIPRANKS
·
04 Feb

Maia Biotechnology Inc - Sees Opportunity for Accelerated FDA Approval of Thio

THOMSON REUTERS
·
04 Feb

Maia Biotechnology Announces Positive Efficacy Updates for Phase 2 Thio-101 Trial in Advanced Non-Small Cell Lung Cancer

THOMSON REUTERS
·
04 Feb

Maia Biotechnology Inc - Third Line Data Shows Median Overall Survival of 16.9 Months

THOMSON REUTERS
·
04 Feb

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

Business Wire
·
04 Feb

MAIA Biotechnology to Present at Biotech Showcase 2025

Business Wire
·
10 Jan

MAIA Biotechnology Shares Rise After Supply Agreement With BeiGene

Dow Jones
·
08 Jan

MAIA Biotechnology enters clinical supply agreement with BeiGene for THIO

TIPRANKS
·
07 Jan

Maia Biotechnology: Under Deal, Maia to Sponsor, Fund Planned Clinical Trials & Beigene Will Provide Tislelizumab

THOMSON REUTERS
·
07 Jan